Study guide
8.2 Gout, Pain & Rheumatologic Care
DHA Pharmacist Licensing Assessment PHO5481
Track your progress as you read
Finished sections get a check mark.
1 Exam Overview & Licensing Pathway
1.1 Current Exam Facts & Format 1.2 Eligibility, PQR & the Sheryan Application Process 1.3 Study Strategy & Test-Day Plan
2 Cardiovascular Pharmacology
2.1 Antihypertensives & RAAS Agents 2.2 Heart Failure & Antiarrhythmic Drugs 2.3 Lipid-Lowering & Antianginal Agents
3 Endocrine & Metabolic Pharmacology
3.1 Insulin & Oral Antidiabetic Agents 3.2 Thyroid, Bone & Calcium Agents 3.3 Corticosteroids & Other Hormonal Agents
4 Anti-Infective Pharmacology
4.1 Beta-Lactam Antibiotics 4.2 Non-Beta-Lactam Antibacterials 4.3 Antifungals, Antivirals & Antituberculars
5 CNS, Psychiatric & Pain Pharmacology
5.1 Psychiatric Pharmacology 5.2 Antiepileptics & Neurologic Agents 5.3 Analgesics: NSAIDs, Opioids & Migraine
6 Respiratory, GI & Hematology Pharmacology
6.1 Respiratory Pharmacology 6.2 Gastrointestinal Pharmacology 6.3 Anticoagulants, Antiplatelets & Hematology Agents
7 Pharmaceutical Care: Cardiometabolic Disease
7.1 Diabetes Management & Counseling 7.2 Hypertension & Dyslipidemia Management 7.3 Heart Failure & Anticoagulation Management
8 Pharmaceutical Care: Respiratory, Rheumatology & Infection
8.1 Asthma & COPD Management 8.2 Gout, Pain & Rheumatologic Care 8.3 Infection Management & Antimicrobial Stewardship
9 Counseling, Monitoring & Special Populations
9.1 Patient Counseling, Adherence & Health Literacy 9.2 Therapeutic Monitoring & Laboratory Interpretation 9.3 Pregnancy, Pediatrics, Geriatrics & Organ Impairment 9.4 Pharmacoeconomics & Formulary Decision Making
10 Pharmaceutical Calculations I
10.1 Concentration, Ratio & Percentage Strength 10.2 Weight-Based & BSA Dosing 10.3 Dilution, Concentration & Alligation
11 Pharmaceutical Calculations II
11.1 Infusion Rates & IV Flow Calculations 11.2 Dispensing Quantities & Days' Supply 11.3 Compounding Calculations, Isotonicity & Milliequivalents
12 UAE Pharmacy Law & Regulation
12.1 UAE Regulatory Framework & Licensing Authorities 12.2 Medicine Registration, Pricing & Supply Chain 12.3 Prescription Requirements & Validity
13 Controlled Drugs, Ethics & Pharmacovigilance
13.1 Controlled & Semi-Controlled Medicines in the UAE 13.2 Ethics, Confidentiality & Generic Substitution 13.3 Pharmacovigilance, Recall & Medicine Disposal
14 Pharmacokinetics I: ADME
14.1 Absorption & Bioavailability 14.2 Distribution & Protein Binding 14.3 Metabolism & Elimination
15 Pharmacokinetics II: Kinetics, Dosing & TDM
15.1 Half-Life, Clearance & Kinetic Order 15.2 Loading & Maintenance Dosing 15.3 Therapeutic Drug Monitoring
16 OTC Medicines & Self-Care
16.1 Cough, Cold & Allergic Rhinitis 16.2 GI Self-Care: Heartburn, Constipation & Diarrhoea 16.3 Pain & Fever Self-Care 16.4 Referral Red Flags, Emergency Contraception & Skin
17 Medication Safety
17.1 High-Alert Medications & Error-Prone Abbreviations 17.2 Medication Reconciliation & Duplicate Therapy 17.3 Adverse Drug Reactions & Hypersensitivity Recognition
18 Sterile & Nonsterile Compounding
18.1 Aseptic Technique & Compounding Environments 18.2 Parenteral, TPN & Cytotoxic Preparation 18.3 Nonsterile Compounding
19 Pharmaceutics, Biopharmaceutics & Toxicology
19.1 Dosage Form Design & the Biopharmaceutics Classification System 19.2 Dissolution & Excipients 19.3 Toxicology: Poisoning Recognition & Antidotes
20 Infection Control, Natural Products, Medicinal Chemistry & Pharmacogenomics
20.1 Infection Control & Immunization 20.2 Pharmacognosy & Dietary Supplements 20.3 Medicinal Chemistry Essentials 20.4 Clinical Pharmacogenomics
8.2 Gout, Pain & Rheumatologic Care
Key Takeaways Explain This Topic AI
Treat acute gout flares early with an NSAID, low-dose colchicine, or a corticosteroid; never stop an established allopurinol during a flare
Allopurinol is started low (100 mg daily; 50 mg in renal impairment) and titrated to a target serum urate below 360 µmol/L — below 300 µmol/L in severe tophaceous disease
HLA-B*58:01 screening before allopurinol is recommended in high-risk ethnicities, including some South Asian and Middle Eastern populations, to reduce the risk of severe cutaneous hypersensitivity
Flare prophylaxis with low-dose colchicine (or a low-dose NSAID) for 3–6 months is required when initiating or titrating urate-lowering therapy
Methotrexate is dosed once weekly on the same day each week, co-prescribed with folic acid, and monitored with full blood count, liver function, and renal function
Last updated: August 2026
Acute Gout Flare Management
Gout is a monosodium urate crystal arthropathy presenting as sudden, exquisitely painful monoarthritis — classically the first metatarsophalangeal joint (podagra). Before treating a first-ever hot swollen joint, consider the red flag of septic arthritis , which may need joint aspiration and urgent admission. Once gout is established as the diagnosis, the care principle is treat the flare early and aggressively , with the agent chosen according to comorbidities:
NSAID (e.g., naproxen or indomethacin at full anti-inflammatory dose) if there is no renal impairment, peptic ulcer disease, or cardiovascular contraindication; add a proton pump inhibitor for gastroprotection where risk factors exist.
Colchicine at low dose — for example 1 mg then 0.5 mg one hour later, or 0.5 mg two to three times daily — is as effective as historical high-dose regimens with far less gastrointestinal toxicity. Reduce the dose in renal impairment and beware interactions with clarithromycin, ciclosporin, and statins, which can cause colchicine accumulation.
Corticosteroid — oral prednisolone (e.g., 30–35 mg daily for 3–5 days) or intra-articular injection — is preferred when NSAIDs and colchicine are unsuitable, such as in chronic kidney disease.
The most examined rule: in a patient already established on allopurinol, do NOT stop it during a flare — treat the flare on top and continue the urate-lowering drug unchanged, because interrupting it causes urate fluctuations that can prolong the attack. Traditional practice also avoided starting urate-lowering therapy mid-flare; current American College of Rheumatology guidance conditionally permits initiation during a flare, but the unchanging exam point is that an established user must never have it stopped. Adjunctive measures include rest, ice packs, and simple analgesia.
Urate-Lowering Therapy (ULT)
Offer long-term ULT to patients with recurrent flares, tophi, chronic kidney disease, urolithiasis, or diuretic-driven hyperuricaemia.
Allopurinol first line, start-low-go-slow : begin at 100 mg daily (50 mg daily in significant renal impairment) and titrate every 2–4 weeks against the serum urate. Under-dosing is the most common real-world reason for treatment failure.
Treat-to-target serum urate : below 360 µmol/L (6 mg/dL) for most patients; below 300 µmol/L (5 mg/dL) in severe disease with tophi or frequent flares, to accelerate crystal dissolution. Check urate a few weeks after each dose change and periodically once at target; therapy is usually lifelong, and adherence is the main determinant of success.
HLA-B*58:01 screening : carriers have a much higher risk of allopurinol hypersensitivity syndrome, a potentially fatal severe cutaneous reaction. Screening before initiation is recommended in high-risk ethnicities — Han Chinese, Thai, Korean, African ancestry, and some South Asian and Middle Eastern populations — making it directly relevant to UAE practice. Counsel every patient to stop allopurinol and seek urgent care at the first sign of rash.
Febuxostat is the usual alternative when allopurinol is not tolerated or ineffective, but use with cardiovascular caution — the CARES trial showed higher cardiovascular mortality in patients with established cardiovascular disease.
Flare prophylaxis on initiation : starting or up-titrating ULT transiently increases flares, so co-prescribe colchicine 0.5 mg daily (or a low-dose NSAID) for 3–6 months and explain why, so the patient does not abandon therapy when an early flare occurs.
Lifestyle : reduce beer and spirits, purine-rich foods (organ meats, certain seafood), and sugar-sweetened drinks; encourage weight loss, good hydration, and review of diuretic therapy where an alternative exists.
Osteoarthritis versus Rheumatoid Arthritis
- Feature Osteoarthritis Rheumatoid arthritis
- Pattern Mechanical, worsens with use Inflammatory, symmetrical small joints
- Morning stiffness Brief (<30 minutes) Prolonged (>1 hour)
- Serology None Rheumatoid factor / anti-CCP
- Care focus Exercise, weight, topical NSAIDs first Early DMARD referral to suppress disease
For OA, NICE-style care emphasises therapeutic exercise and weight management, topical NSAIDs first for knee and hand disease, and the lowest oral NSAID dose for the shortest time with PPI cover when gastrointestinal risk factors exist; paracetamol has only a limited role. For RA, disease-modifying antirheumatic drugs (DMARDs) alter the disease course and must be started early by a specialist. Methotrexate is the anchor drug; other conventional options include sulfasalazine, hydroxychloroquine, and leflunomide (also teratogenic), with biologic DMARDs reserved for inadequate response after infection screening. Critical pharmacist counseling for methotrexate: taken once weekly on the same day each week (inadvertent daily dosing has caused fatal toxicity), co-prescribed with folic acid taken on a different day, with baseline and regular monitoring of full blood count, liver function tests, and renal function ; it is contraindicated in pregnancy, so contraception counseling is essential. NSAIDs and short corticosteroid courses relieve RA symptoms only — they do not modify disease — and chronic NSAID use requires gastrointestinal, cardiovascular, and renal risk assessment.
Chronic Pain and Opioid Stewardship
Build care on multimodal non-drug approaches : structured physical activity, physiotherapy, psychological therapies such as cognitive behavioural therapy, weight management, and sleep hygiene.
Opioids are not first-line for chronic non-cancer pain , and there is little evidence of long-term benefit. If trialled, apply stewardship: lowest effective dose, time-limited course, agreed functional goals, and regular face-to-face review.
Tapering : when harms outweigh benefits, reduce gradually — for example around 5–10% of the dose every 2–4 weeks, individualised to the patient — with support to minimise withdrawal and flare anxiety.
Naloxone provision : offer or discuss take-home naloxone for patients on high opioid doses, those combining opioids with benzodiazepines or other sedatives, or those with a history of opioid use disorder, where local availability permits, and educate household members on recognising opioid-induced respiratory depression.
Screen for misuse: early refill requests, escalating doses, sedation, and obtaining opioids from multiple prescribers. In the UAE context, note that tramadol and stronger opioid analgesics are tightly controlled medicines — prescribing and dispensing rules, including prescription validity and record-keeping, are strictly enforced by health authorities.